CXCL10 and neoplasm: Furthermore, the phase I clinical trial assessing the efficacy and safety of locoregional delivery of HER2-CAR T-cells via central nervous system (CNS) catheter to the tumor cavity or the ventricular system of children and young adults with R/R CNS tumors found significant immune responses as demonstrated by increment in C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 10 (CXCL10) levels, with no dose-limiting adverse reactions (NCT03500991) (64).